Doctor of Dentistry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sung Hee Cho

Oral & Maxillofacial Surgery River Edge, NJ Doctor of Dentistry

NPI 1427220029 CMS profile 1144346

130 Kinderkamack Rd Ste 204, River Edge, NJ 07661

Open in the dashboard

General payments

$10,440

58 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sung Hee Cho of River Edge, NJ is reported in the CMS Open Payments database as having received $10,440 across 58 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Oral & Maxillofacial Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $46 2
2024 General $6,938 2
2023 General $338 6
2022 General $1,006 16
2021 General $274 7
2020 General $81 3
2019 General $1,756 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sung Hee Cho
  • Oral & Maxillofacial Surgery median
  • Middle half of Oral & Maxillofacial Surgery
  • National median

In program year 2025, general payments to Sung Hee Cho were reported at $46. Among 792 Oral & Maxillofacial Surgery profiles paid that year, the median was $184 and the middle half received between $61 and $541.

Show as a table
Year Sung Hee Cho Oral & Maxillofacial Surgery median Middle half National median
2019 $1,756 $178 $56–$584 $163
2020 $81 $106 $38–$316 $114
2021 $274 $165 $57–$511 $132
2022 $1,006 $173 $63–$494 $149
2023 $338 $184 $62–$521 $160
2024 $6,938 $197 $65–$603 $164
2025 $46 $184 $61–$541 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $6,925 1 payment
  2. Straumann USA LLC $1,761 27 payments
  3. Zimvie Inc. $529 9 payments
  4. Carestream Dental, LLC $524 6 payments
  5. Geistlich Pharma, North America, Inc. $292 4 payments
  6. Thommen Medical USA, LLC $254 2 payments
  7. Nobel Biocare USA $60 4 payments
  8. Zimmer Biomet Holdings, Inc. $50 2 payments
  9. Implant Direct Sybron International LLC $19 1 payment
  10. AstraZeneca Pharmaceuticals LP $13 1 payment
  11. Other $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,925 1 payment
  2. Food and Beverage $2,878 49 payments
  3. Education $275 3 payments
  4. Travel and Lodging $219 1 payment
  5. Gift $130 3 payments
  6. Entertainment $12 1 payment
Products named General payments · program years 2019–2025
  1. Bio-Materials $292 4 payments
  2. Tapered Screw-Vent $160 2 payments
  3. BioSet $132 2 payments
  4. Bellatek $100 1 payment
  5. 3i T3 $100 1 payment
  6. NOBELACTIVE $60 4 payments
  7. NOBELPARALLEL $60 4 payments
  8. Tapered Screw $30 1 payment
  9. BioMend $20 1 payment
  10. LEGACY SYSTEM $19 1 payment
  11. Other $26 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

389

Median for Oral & Maxillofacial Surgery: 284

Drug cost

$2,135

Median for Oral & Maxillofacial Surgery: $1,067

Branded share of claims

36.2%

Median for Oral & Maxillofacial Surgery: 17.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 129 $665
Amoxicillin Generic 160 $583
Dexamethasone Generic 14 $341
Clindamycin Hcl Generic 38 $273
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 12 $161
Chlorhexidine Gluconate Generic 36 $112

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 600 Part D prescribers listed as Oral & Maxillofacial Surgery; they describe a distribution and say nothing about conduct.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BREZTRI
  • AstraZeneca Pharmaceuticals LP $13
$13 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

58 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Oral & Maxillofacial Surgery in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record